Director/PDMR Shareholding

AstraZeneca PLC
02 April 2007



Transaction by Persons Discharging Managerial Responsibilities
Disclosure Rules DR 3.1.2R

We hereby inform you that on 30 March 2007, the following individuals, who are
all persons discharging managerial responsibilities, were each granted an award
under the terms of the AstraZeneca Performance Share Plan over the Company's
USD0.25 Ordinary Shares or, in the case of A Zook, over the Company's American
Depositary Shares (ADSs).  One ADS equals one Ordinary Share

                       Target number         Award price 
                       of shares awarded     per share      Normal vesting date
Name of individual

B Angelici             24,665                2744p          30 March 2010

A P Bloxham            13,591                2744p          30 March 2010

J Lundberg             16,994                2744p          30 March 2010

M Nicklasson           21,951                2744p          30 March 2010

D Smith                16,399                2744p          30 March 2010

A Zook                 40,817                US$53.80       30 March 2010

The AstraZeneca Performance Share Plan was approved by shareholders at the
Company's AGM in 2005.  Awards made under the Plan may not generally vest before
the third anniversary of the relevant date of grant nor unless the specified
performance target(s) have been met at the end of the three year period which,
for this award, is 1 January 2007 to 31 December 2009.

The performance target that applies to this award is the Company's Total
Shareholder Return ('TSR') compared to the TSR of a selected peer group of 12
other pharmaceutical companies.  The actual number of shares to which a
participant may become unconditionally entitled will depend on the extent to
which the performance target(s) have been met.  A summary of the Plan, including
a more detailed explanation of the performance target(s), can be found in the
AstraZeneca Annual Report and Form 20-F Information 2006 which is available on
the Company's website www.astrazeneca.com.


G H R Musker
Company Secretary
2 April 2007



                      This information is provided by RNS
            The company news service from the London Stock Exchange